Saturday, October 3, 2026

USD/CNH Bearish Momentum: 0.92% Down In The Last 10 Sessions

USD/CNH Bearish Momentum: 0.92% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 0.92% for the last 10 sessions. At 23:06 EST on Tuesday, 2 April, USD/CNH (USDCNH) is $7.25.

USD/CNH's yearly highs and lows, it's 0.036% up from its 52-week low and 0.08% down from its 52-week high.

News about

  • Eur/usd price analysis: maintains position below the psychological level of 1.0800. According to FXStreet on Monday, 1 April, "A break below this level could lead the EUR/USD pair to navigate the area around the psychological level of 1.0700.", "A breakthrough above this barrier could lead the EUR/USD pair to explore the region around the 23.6% Fibonacci retracement level of 1.0818 and the nine-day Exponential Moving Average (EMA) at 1.0820. "
  • Eur/usd price analysis: the next contention level is seen at 1.0720, oversold RSI condition eyed. According to FXStreet on Tuesday, 2 April, "The upbeat US ISM Manufacturing PMI for March lifts the US Dollar (USD) and drags the EUR/USD pair lower. ", "The EUR/USD pair extends its downside to 1.0730, the weekly low during the early European session on Tuesday. "
  • Eur/usd trades on a weaker note below 1.0800, investors await the US PMI data. According to FXStreet on Monday, 1 April, "The EUR/USD pair trades on a weaker note near 1.0787 on the renewed US dollar (USD) demand during the early Asian session on Monday. ", "The higher-for-longer stance from the Federal Reserve (Fed) provides some support to the Greenback and weighs on the EUR/USD pair. "
  • Eur/usd attracts some sellers near 1.0730, eyes on fedspeaks. According to FXStreet on Tuesday, 2 April, "The EUR/USD pair remains under selling pressure, reaching nearly weekly lows of 1.0730 on Tuesday during the early Asian trading hours. ", "The dovish comments from the ECB policymakers exert some selling pressure on the Euro (EUR) and act as a headwind for the EUR/USD pair. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com